PL374656A1 - Combinations of atorvastatin and alpha1, adrenergic receptor antagonists - Google Patents

Combinations of atorvastatin and alpha1, adrenergic receptor antagonists

Info

Publication number
PL374656A1
PL374656A1 PL03374656A PL37465603A PL374656A1 PL 374656 A1 PL374656 A1 PL 374656A1 PL 03374656 A PL03374656 A PL 03374656A PL 37465603 A PL37465603 A PL 37465603A PL 374656 A1 PL374656 A1 PL 374656A1
Authority
PL
Poland
Prior art keywords
alpha1
atorvastatin
combinations
receptor antagonists
adrenergic receptor
Prior art date
Application number
PL03374656A
Other languages
Polish (pl)
Inventor
Nicholas Pullen
Richard James Thurlow
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of PL374656A1 publication Critical patent/PL374656A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PL03374656A 2002-09-17 2003-09-05 Combinations of atorvastatin and alpha1, adrenergic receptor antagonists PL374656A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0221579.6A GB0221579D0 (en) 2002-09-17 2002-09-17 Combinations of atorvastatin and, adrenergic receptor antagonists

Publications (1)

Publication Number Publication Date
PL374656A1 true PL374656A1 (en) 2005-10-31

Family

ID=9944250

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03374656A PL374656A1 (en) 2002-09-17 2003-09-05 Combinations of atorvastatin and alpha1, adrenergic receptor antagonists

Country Status (10)

Country Link
EP (1) EP1542677A1 (en)
CN (1) CN1681492A (en)
AU (1) AU2003263420A1 (en)
BR (1) BR0314388A (en)
CA (1) CA2498894A1 (en)
GB (1) GB0221579D0 (en)
PL (1) PL374656A1 (en)
TW (1) TW200407123A (en)
WO (1) WO2004026300A1 (en)
ZA (1) ZA200502225B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100418529C (en) * 2006-06-30 2008-09-17 南京美瑞制药有限公司 Application of Nepider in preparing medicine to accelerate ejection of calculus for urinary system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1238011B (en) * 1989-12-13 1993-06-21 Pulitzer Italiana Pharmaceutical composition with an HMG - COA reductase inhibitor base, for treatment of benign prostatic hypertrophy (enlarged prostate gland)
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GT199800126A (en) * 1997-08-29 2000-01-29 COMBINATION THERAPY.
US6534537B2 (en) * 2000-01-07 2003-03-18 Kenneth Weisman Use of HMG-COA reductase inhibitors to prevent and treat BPH
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
CA2498894A1 (en) 2004-04-01
CN1681492A (en) 2005-10-12
TW200407123A (en) 2004-05-16
BR0314388A (en) 2005-07-19
WO2004026300A1 (en) 2004-04-01
EP1542677A1 (en) 2005-06-22
ZA200502225B (en) 2006-02-22
AU2003263420A1 (en) 2004-04-08
GB0221579D0 (en) 2002-10-23

Similar Documents

Publication Publication Date Title
AU2003261392A8 (en) M3muscarinic acetylcholine receptor antagonists
IL165280A0 (en) 4-Substituted imidazole-2-thiones and imidazol-2-ones as agpmosts of the alpha-2b and alpha-2c adrenergic receptors
PT1638969E (en) Cgrp receptor antagonists
IL165841A0 (en) Mchir antagonists
HK1083188A1 (en) Diaryl ethers as opioid receptor antagonists
IL174538A0 (en) Thrombin receptor antagonists
EP1553075A4 (en) Lpa receptor antagonists
IL162825A0 (en) Fluoro substituted cycloalkanoindoles and their use asprotaglandin d2 receptor antagonists
EP1351933A4 (en) Il-8 receptor antagonists
PL376509A1 (en) Antagonists il-15
AU2003255501A1 (en) Cxcr4 receptor antagonists
EP1536813A4 (en) Compositions and methods comprising protein activated receptor antagonists
IL160942A0 (en) Compounds having partial dopamine-d2 receptor agonist plus serotonin and/or noradrenaline inhibitor activity
PL378753A1 (en) Ccr-3 receptor antagonists
IL163939A0 (en) Nk1 antagonists
IL164016A0 (en) Azetidine derivatives as ccr-3 receptor antagonists
IL165727A0 (en) Chemokine antagonists
AU2003260072A8 (en) Antagonists of chemokine receptors
AU2003240705A1 (en) Morpholinylmethylureas ccr-3 receptor antagonists
AU2003287219A8 (en) Il-8 receptor antagonists
AU2002359524A8 (en) P2x7 receptor antagonists
GB0203412D0 (en) 5-HT 2B receptor antagonists
PL374656A1 (en) Combinations of atorvastatin and alpha1, adrenergic receptor antagonists
GB0101223D0 (en) Histamine receptor antagonists
AU2003223329A8 (en) Antagonists of rf-amide neuropeptides

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)